Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of verbascoside

A technology of verbascoside and products, which is applied in the field of medicine to achieve the effects of lowering blood lipid levels, reducing foaming degree, and reducing lipid deposition

Pending Publication Date: 2022-08-02
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Acteoside has positive effects on neuroprotection, anti-tumor, anti-depression, anti-inflammation, etc. Another study shows that total glycosides of Cistanche deserticola has the effect of lowering blood sugar and lipids, but acteoside itself has no effect on anti-atherosclerosis research report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of verbascoside
  • New application of verbascoside
  • New application of verbascoside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Studies on the anti-atherosclerotic activity of verbascoside in vitro.

[0026] experimental method

[0027] 1. Cell culture: Take RAW264.7 macrophages and add them to DMEM high-glucose medium containing 10% fetal bovine serum, and place the cells at 37°C, 5% CO 2 cultured in an incubator.

[0028] 2. Oil red O staining to identify the effect of verbascoside on foaming of macrophages

[0029] 2.1 The above logarithmic growth phase RAW264.7 cells were seeded in a 96-well plate with 8000 cells per well, and the cells were cultured in the incubator for 24 hours and divided into blank group, model group and verbascoside administration group. Group 5 duplicate wells. The model group was given serum-free medium with a concentration of 50 μg / mL oxidized low-density lipoprotein (Ox-LDL) to continue culturing, and the verbascoside-administered group was given a concentration of 50 μg / mL Ox-LDL plus 10 μM of the verbascoside obtained in Example 1. Co-culture with serum-free m...

Embodiment 2

[0040] Studies on the anti-atherosclerotic activity of verbascoside in vivo.

[0041] experimental method

[0042] 1. Animal grouping and administration: 10 8-week-old male C57BL / 6J mice were used as the control group (i.g. saline), and 50 8-week-old male Apo E - / - Gene knockout mice were randomly divided into model group (i.g. normal saline), simvastatin positive drug group (i.g. 20 mg / kg / day), low-dose group of verbascoside (i.g. 15 mg / kg / day), and medium-dose group of verbascoside. (i.g. 30 mg / kg / day), high-dose group (i.g. 60 mg / kg / day) of verbascoside. The control group was given ordinary feed, and the model group and each administration group were given high-fat feed for 16 weeks. The mouse aorta was fixed with 10% paraformaldehyde, and the mouse plasma and liver were collected and stored for testing.

[0043] 2. Frozen section of the aortic root, immersed in oil red staining solution for 10 min, washed with distilled water; differentiated with 60% isopropanol, washed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides the application of the verbascoside in the preparation of the medicine for preventing and / or treating hyperlipidemia and atherosclerosis, the application prospect of the verbascoside is developed, and a theoretical basis and guidance are provided for the development of a new medicine for resisting atherosclerosis. The verbascoside is proved to be capable of remarkably reducing the foaming degree of oxidized low-density lipoprotein induced macrophages in vitro, reducing the cholesterol level and remarkably relieving formation of arterial plaques in a western diet induced atherosclerosis animal model at the same time; the verbascoside can relieve lipid deposition in the liver by adjusting a glycerophospholipid metabolic pathway in the liver, adjust lipid metabolism disorder and reduce the blood fat level, so that the effect of resisting atherosclerosis is achieved.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the new use of verbascoside. Background technique [0002] Atherosclerosis (AS) is a disease in which atherosclerotic plaques composed of fat, cholesterol, calcium and other substances in the blood build up in the walls of blood vessels and narrow the arteries. In recent years, due to the improvement of people's living standards, excessive intake of unsaturated fatty acids, trans fatty acids, carbonated beverages, smoking and drinking and other unhealthy lifestyle habits lead to disorders of lipid metabolism in the human body, increasing the risk of atherosclerosis. At present, lipid-lowering drugs represented by statins are widely used in the treatment of clinical atherosclerosis, but their dose-dependent and time-dependent adverse reactions such as myalgia and myositis cause trouble for the majority of patients. [0003] Verbasicose glycosides are phenylethanoid glycosides, w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7032A61P3/06A61P9/10A61P1/16A23L33/125
CPCA61K31/7032A61P3/06A61P9/10A61P1/16A23L33/125A23V2002/00A23V2200/326A23V2200/3262A23V2200/32
Inventor 姜苗苗雷鹏吕佳霖王跃飞张鹏柴欣崔英杨静
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com